broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
float64 | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-K63504947-001-14-7 | ACH-000950 | LOVO_LARGE_INTESTINE | MTS010 | 1 | 0.7521 | -0.186728 | -0.024745 | 0.842888 | 1.787117 | null | semaxanib | VEGFR inhibitor | FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET | null | null | Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1 | Phase 3 | true | ACH-000950 |
BRD-K63712959-001-01-8 | ACH-000950 | LOVO_LARGE_INTESTINE | MTS010 | 1 | 1.366785 | 2.449484 | 0.204862 | 1 | 0.96903 | null | temoporfin | radical formation stimulant | null | oncology | head and neck squamous cell carcinoma (HNSCC) | Oc1cccc(c1)-c1c2CCc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2 | Launched | true | ACH-000950 |
BRD-K64052750-001-22-5 | ACH-000950 | LOVO_LARGE_INTESTINE | MTS010 | 1 | 0.29238 | 0.748999 | 0.119551 | 0.76248 | 0.430065 | 1.390423 | gefitinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1 | Launched | true | ACH-000950 |
BRD-K64881305-001-03-7 | ACH-000950 | LOVO_LARGE_INTESTINE | MTS010 | 1 | 0.37121 | 0.001906 | -0.001131 | 0.708091 | 34,505,048,930,319,403,000,000,000,000,000 | null | ispinesib | kinesin inhibitor | KIF11 | null | null | CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1 | Phase 2 | true | ACH-000950 |
BRD-K66175015-001-12-4 | ACH-000950 | LOVO_LARGE_INTESTINE | MTS010 | 1 | 0.462656 | 1.919482 | 0.560673 | 0.581159 | 0.005141 | 0.019864 | afatinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | oncology | non-small cell lung cancer (NSCLC) | CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1 | Launched | true | ACH-000950 |
BRD-K67844266-003-01-9 | ACH-000950 | LOVO_LARGE_INTESTINE | MTS010 | 1 | 0.682428 | 7.944621 | 0.200077 | 0.886918 | 0.315663 | null | pevonedistat | nedd activating enzyme inhibitor | NAE1, UBA3 | null | null | NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12 | Phase 2 | true | ACH-000950 |
BRD-K69001009-001-02-8 | ACH-000950 | LOVO_LARGE_INTESTINE | MTS010 | 1 | 0.492737 | 1.923777 | -0.421861 | 0.64703 | 0.011655 | 0.105163 | golvatinib | VEGFR inhibitor | KDR, MET | null | null | CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1 | Phase 2 | true | ACH-000950 |
BRD-K69694239-001-02-2 | ACH-000950 | LOVO_LARGE_INTESTINE | MTS010 | 1 | 0.369896 | 0.509262 | -0.13227 | 0.793653 | 0.598239 | 8.413224 | bardoxolone-methyl | nuclear factor erythroid derived, like (NRF2) activator | PPARG, STAT3 | null | null | COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 | Phase 3 | true | ACH-000950 |
BRD-K69776681-001-03-8 | ACH-000950 | LOVO_LARGE_INTESTINE | MTS010 | 1 | 0.400756 | 0.640342 | 0.083748 | 0.613749 | 0.016479 | 0.205893 | volasertib | PLK inhibitor | PLK1 | null | null | CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O | Phase 3 | true | ACH-000950 |
BRD-K70301465-001-05-9 | ACH-000950 | LOVO_LARGE_INTESTINE | MTS010 | 1 | 0.643685 | 0.119144 | 0.006487 | 0.888167 | 65.879436 | null | ibrutinib | Bruton's tyrosine kinase (BTK) inhibitor | BLK, BMX, BTK | hematologic malignancy | chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM) | Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C | Launched | true | ACH-000950 |
BRD-K70401845-001-15-7 | ACH-000950 | LOVO_LARGE_INTESTINE | MTS010 | 1 | 0.582764 | 0.102151 | -0.067715 | 0.738866 | 0.000459 | null | erlotinib | EGFR inhibitor | EGFR, NR1I2 | oncology | non-small cell lung cancer (NSCLC), pancreatic cancer | COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC | Launched | true | ACH-000950 |
BRD-K73838513-003-05-5 | ACH-000950 | LOVO_LARGE_INTESTINE | MTS010 | 1 | 0.661468 | 0.179617 | -0.013677 | 0.796302 | 0.006817 | null | cinacalcet | calcium channel activator | CASR | endocrinology, nephrology, oncology | hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia | C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12 | Launched | true | ACH-000950 |
BRD-K74514084-003-09-2 | ACH-000950 | LOVO_LARGE_INTESTINE | MTS010 | 1 | 0.586089 | 0.166215 | -0.130256 | 0.711013 | 0.000389 | null | pazopanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3 | oncology | renal cell carcinoma (RCC), soft tissue sarcoma (STS) | CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1 | Launched | true | ACH-000950 |
BRD-K75009076-001-02-1 | ACH-000950 | LOVO_LARGE_INTESTINE | MTS010 | 1 | 0.334261 | 1.523774 | 0.456693 | 0.719969 | 0.168924 | 0.348658 | SCH-900776 | CHK inhibitor | CDK2, CHEK1 | null | null | Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1 | Phase 2 | true | ACH-000950 |
BRD-K76210423-001-01-6 | ACH-000950 | LOVO_LARGE_INTESTINE | MTS010 | 1 | 0.73105 | 4.897944 | -0.012544 | 0.890027 | 0.189076 | null | resiquimod | toll-like receptor agonist | TLR7, TLR8 | null | null | CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O | Phase 3 | true | ACH-000950 |
BRD-K76239644-001-02-6 | ACH-000950 | LOVO_LARGE_INTESTINE | MTS010 | 1 | 0.068909 | -0.104932 | -0.097094 | 0.689121 | 0.000094 | null | BMS-690514 | EGFR inhibitor, VEGFR inhibitor | EGFR, ERBB2, FLT3, KDR | null | null | COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1 | Phase 2 | true | ACH-000950 |
BRD-K76674262-001-03-3 | ACH-000950 | LOVO_LARGE_INTESTINE | MTS010 | 1 | 0.40088 | 0.064921 | -0.225575 | 0.665626 | 0.002079 | null | homoharringtonine | protein synthesis inhibitor | RPL3 | hematologic malignancy | chronic myeloid leukemia (CML) | COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC | Launched | true | ACH-000950 |
BRD-K76908866-001-07-6 | ACH-000950 | LOVO_LARGE_INTESTINE | MTS010 | 1 | 0.828638 | -7.442541 | 0.276974 | 0.863518 | 1.387196 | null | CP-724714 | EGFR inhibitor, protein tyrosine kinase inhibitor | ERBB2 | null | null | COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1 | Phase 2 | true | ACH-000950 |
BRD-K77625799-001-07-7 | ACH-000950 | LOVO_LARGE_INTESTINE | MTS010 | 1 | 0.764767 | 4.650045 | 0.111676 | 0.938258 | 0.783023 | null | vandetanib | EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA | oncology | medullary thyroid cancer (MTC) | COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1 | Launched | true | ACH-000950 |
BRD-K78431006-001-15-1 | ACH-000950 | LOVO_LARGE_INTESTINE | MTS010 | 1 | 0.424675 | 1.638084 | -0.094877 | 0.64648 | 0.025683 | 0.081559 | crizotinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl | Launched | true | ACH-000950 |
BRD-K81016934-001-02-0 | ACH-000950 | LOVO_LARGE_INTESTINE | MTS010 | 1 | 0.334336 | -0.011202 | -0.132185 | 0.672141 | 0.005419 | null | INC-280 | c-Met inhibitor | MET | null | null | CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1 | Phase 2 | true | ACH-000950 |
BRD-K81418486-001-44-2 | ACH-000950 | LOVO_LARGE_INTESTINE | MTS010 | 1 | 0.342517 | -0.693318 | -0.012362 | 0.959429 | 0.000235 | null | vorinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9 | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1 | Launched | true | ACH-000950 |
BRD-K81473043-001-19-5 | ACH-000950 | LOVO_LARGE_INTESTINE | MTS010 | 1 | 1.341941 | 0.020894 | -0.037855 | 1 | 0.03601 | null | tanespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 3 | true | ACH-000950 |
BRD-K82135108-001-04-3 | ACH-000950 | LOVO_LARGE_INTESTINE | MTS010 | 1 | 0.698753 | -0.055017 | -0.151749 | 0.864516 | 0.000983 | null | elesclomol | oxidative stress inducer | HSPA1A | null | null | CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1 | Phase 3 | true | ACH-000950 |
BRD-K82746043-001-19-3 | ACH-000950 | LOVO_LARGE_INTESTINE | MTS010 | 1 | 0.447657 | -0.006627 | -0.199362 | 0.721267 | 1.283976 | null | navitoclax | BCL inhibitor | BCL2, BCL2L1, BCL2L2 | null | null | CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 | Phase 2 | true | ACH-000950 |
BRD-K82818427-001-04-8 | ACH-000950 | LOVO_LARGE_INTESTINE | MTS010 | 1 | 0.855447 | 0.224355 | -0.134595 | 0.88902 | 0.000239 | null | batimastat | matrix metalloprotease inhibitor | ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8 | null | null | CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO | Phase 3 | true | ACH-000950 |
BRD-K83029223-001-01-3 | ACH-000950 | LOVO_LARGE_INTESTINE | MTS010 | 1 | 0.486843 | -0.004758 | -0.047428 | 0.744265 | 0.001225 | null | litronesib | kinesin-like spindle protein inhibitor | KIF11 | null | null | CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 | Phase 2 | true | ACH-000950 |
BRD-K83988098-001-02-0 | ACH-000950 | LOVO_LARGE_INTESTINE | MTS010 | 1 | 0.666049 | -1.567568 | -0.185612 | 0.947764 | 0.000032 | null | alvespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 2 | true | ACH-000950 |
BRD-K85402309-043-01-9 | ACH-000950 | LOVO_LARGE_INTESTINE | MTS010 | 1 | 0.667623 | 0.155353 | -0.130909 | 0.826881 | 0.022402 | null | dovitinib | EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB | null | null | CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O | Phase 3 | true | ACH-000950 |
BRD-K86118762-001-01-8 | ACH-000950 | LOVO_LARGE_INTESTINE | MTS010 | 1 | 0.781895 | -3.414171 | 0.440463 | 0.836945 | 0.863445 | null | linsitinib | IGF-1 inhibitor | IGF1R, INSR, INSRR | null | null | C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 | Phase 3 | true | ACH-000950 |
BRD-K86972824-001-01-4 | ACH-000950 | LOVO_LARGE_INTESTINE | MTS010 | 1 | 1.032269 | -0.069322 | -0.046787 | 1 | 6.918701 | null | oltipraz | nuclear factor erythroid derived, like (NRF2) activator | ANG | null | null | Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1 | Phase 3 | true | ACH-000950 |
BRD-K87737963-001-06-0 | ACH-000950 | LOVO_LARGE_INTESTINE | MTS010 | 1 | 1.754011 | -0.207861 | -0.332595 | 1 | 0.001868 | null | cyt387 | null | JAK1, JAK2, JAK3 | null | null | O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1 | Phase 3 | true | ACH-000950 |
BRD-K87782578-001-01-4 | ACH-000950 | LOVO_LARGE_INTESTINE | MTS010 | 1 | 0.754638 | 0.061079 | -0.074904 | 0.879159 | 0.128096 | null | AVL-292 | Bruton's tyrosine kinase (BTK) inhibitor | BTK, YES1 | null | null | COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1 | Phase 2 | true | ACH-000950 |
BRD-K87909389-003-03-4 | ACH-000950 | LOVO_LARGE_INTESTINE | MTS010 | 1 | 0.059286 | 0.33009 | 0.302349 | 0.494758 | 0.045406 | 0.066553 | alvocidib | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM | null | null | CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000950 |
BRD-K88510285-001-17-8 | ACH-000950 | LOVO_LARGE_INTESTINE | MTS010 | 1 | 0.293276 | 0.341774 | 0.294158 | 0.73044 | 0.05043 | null | bortezomib | NFkB pathway inhibitor, proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA | hematologic malignancy | multiple myeloma, mantle cell lymphoma (MCL) | CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O | Launched | true | ACH-000950 |
BRD-K89014967-001-04-3 | ACH-000950 | LOVO_LARGE_INTESTINE | MTS010 | 1 | 0.388487 | 0.609262 | 0.515958 | 0.541141 | 0.004581 | 0.053769 | AS-703026 | MEK inhibitor | MAP2K1, MAP2K2 | null | null | OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F | Phase 2 | true | ACH-000950 |
BRD-K96123349-236-02-8 | ACH-000950 | LOVO_LARGE_INTESTINE | MTS010 | 1 | 0.617496 | -5.198638 | 0.41797 | 0.814837 | 0.066923 | null | brequinar | dihydroorotate dehydrogenase inhibitor | DHODH | null | null | Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F | Phase 2 | true | ACH-000950 |
BRD-K98572433-001-02-9 | ACH-000950 | LOVO_LARGE_INTESTINE | MTS010 | 1 | 0.197563 | -0.035194 | -0.060771 | 0.57862 | 1.370599 | null | AZD8931 | EGFR inhibitor | EGFR, ERBB2, ERBB3 | null | null | CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC | Phase 2 | true | ACH-000950 |
BRD-K99113996-001-02-0 | ACH-000950 | LOVO_LARGE_INTESTINE | MTS010 | 1 | 0.558439 | 0.915362 | 0.362051 | 0.695837 | 0.011667 | null | AZD2014 | mTOR inhibitor | MTOR | null | null | CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C | Phase 2 | true | ACH-000950 |
BRD-K99616396-001-05-1 | ACH-000950 | LOVO_LARGE_INTESTINE | MTS010 | 1 | 0.635277 | -0.350879 | 0.060171 | 0.812895 | 0.093738 | null | motesanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT1, FLT4, KDR, KIT | null | null | CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12 | Phase 3 | true | ACH-000950 |
BRD-K99749624-001-07-0 | ACH-000950 | LOVO_LARGE_INTESTINE | MTS010 | 1 | 0.991183 | -0.030676 | -0.032681 | 0.994282 | 37,939,974.229751 | null | linifanib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK | null | null | Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3[nH]nc(N)c23)c1 | Phase 3 | true | ACH-000950 |
BRD-M97302542-001-04-4 | ACH-000950 | LOVO_LARGE_INTESTINE | MTS010 | 1 | 0.892666 | 0.085343 | -0.001062 | 0.929898 | 0.000042 | null | dichloroacetate | pyruvate dehydrogenase kinase inhibitor | PDK1 | null | null | [Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl | Phase 3 | true | ACH-000950 |
BRD-A25234499-001-19-1 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.913224 | -6.599644 | 0.002862 | 0.925601 | 2.505443 | null | aminoglutethimide | glucocorticoid receptor antagonist | CYP11A1, CYP19A1 | endocrinology, oncology | Cushing's syndrome, breast cancer | CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1 | Launched | true | ACH-000954 |
BRD-A70858459-001-01-7 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 192.165179 | 4.569289 | -0.029953 | 1 | 53,320,625.543298 | null | estramustine | DNA alkylating agent | ESR1, ESR2, MAP1A, MAP2 | oncology | prostate cancer | C[C@]12CCC3C(CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)C1CC[C@@H]2O | Launched | true | ACH-000954 |
BRD-A74914197-001-02-9 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.880918 | 0.102439 | 0.012703 | 0.916653 | 0.000001 | null | pralatrexate | dihydrofolate reductase inhibitor | DHFR, TYMS | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 | Launched | true | ACH-000954 |
BRD-K02113016-001-19-6 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 1.301777 | -0.240301 | -0.097504 | 1 | 0.444006 | null | olaparib | PARP inhibitor | PARP1, PARP2 | oncology | ovarian cancer | Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1 | Launched | true | ACH-000954 |
BRD-K02130563-001-11-4 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.110316 | 1.628892 | 0.841146 | 0.505605 | 0.04547 | 0.052989 | panobinostat | HDAC inhibitor | HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | multiple myeloma | Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1 | Launched | true | ACH-000954 |
BRD-K03390685-001-01-7 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 1.181325 | -0.006999 | -0.037176 | 1 | 1,343,427.857297 | null | cobimetinib | MEK inhibitor | null | oncology | melanoma | OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1 | Launched | true | ACH-000954 |
BRD-K03406345-001-21-1 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.820024 | 9.058679 | 0.211612 | 0.9077 | 0.068947 | null | azacitidine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL) | Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000954 |
BRD-K03449891-001-08-6 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | -0.355681 | 4.687487 | 0.39536 | 0.97442 | 9.366177 | 8.351727 | foretinib | VEGFR inhibitor | FLT1, FLT4, KDR, MET | null | null | COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1 | Phase 2 | true | ACH-000954 |
BRD-K03765900-001-01-9 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.236629 | 3.031509 | 0.631898 | 0.922323 | 3.788775 | 4.680963 | XL-647 | EGFR inhibitor, VEGFR inhibitor | EGFR, EPHB4, ERBB2, FLT4, KDR | null | null | COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1 | Phase 3 | true | ACH-000954 |
BRD-K06814349-304-02-7 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.859579 | 0.191539 | -0.065196 | 0.915619 | 0.00794 | null | fosbretabulin | tubulin polymerization inhibitor, VE-cadherin antagonist | CDH5 | null | null | COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O | Phase 3 | true | ACH-000954 |
BRD-K08109215-001-06-4 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 1.076509 | 0.077926 | -0.003063 | 1 | 0.000108 | null | I-BET-762 | bromodomain inhibitor | BRD2, BRD3, BRD4 | null | null | CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 | Phase 2 | true | ACH-000954 |
BRD-K08542803-001-02-3 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.142264 | 3.371685 | 0.468819 | 0.758601 | 0.651403 | 0.719409 | gambogic-acid | caspase activator | BCL2 | null | null | CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C | Phase 2 | true | ACH-000954 |
BRD-K08547377-001-04-4 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 1.275994 | 0.409129 | 0.064137 | 1 | 0.295338 | null | irinotecan | topoisomerase inhibitor | TOP1, TOP1MT | oncology | colorectal cancer | CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12 | Launched | true | ACH-000954 |
BRD-K08703257-001-13-9 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 2.612595 | 1.411992 | 0.154787 | 1 | 11.482315 | null | 3-amino-benzamide | PARP inhibitor | PARP1 | null | null | NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1 | Phase 2 | true | ACH-000954 |
BRD-K08799216-001-05-3 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.217961 | 4.676311 | 0.718904 | 0.875414 | 2.131249 | 2.408843 | pelitinib | EGFR inhibitor | EGFR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 2 | true | ACH-000954 |
BRD-K09951645-001-11-8 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 3.202204 | -2.326712 | 0.061031 | 1 | 0.000322 | null | dabrafenib | RAF inhibitor | BRAF, LIMK1, NEK11, RAF1, SIK1 | oncology | melanoma | CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F | Launched | true | ACH-000954 |
BRD-K11267252-001-05-1 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.99442 | -0.080266 | -0.005252 | 0.996817 | 2.789835 | null | alectinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1 | Launched | true | ACH-000954 |
BRD-K11630072-001-13-2 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 1.202923 | 1.293329 | 0.011038 | 1 | 8.752826 | null | carmofur | thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O | Launched | true | ACH-000954 |
BRD-K12184916-001-19-6 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.768813 | 5.353848 | 0.302574 | 0.884282 | 0.075637 | null | NVP-BEZ235 | mTOR inhibitor, PI3K inhibitor | ATR, MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1 | Phase 2 | true | ACH-000954 |
BRD-K12343256-001-14-7 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 1.48394 | -0.187788 | -0.009592 | 1 | 0.000023 | null | trametinib | MEK inhibitor | MAP2K1, MAP2K2 | oncology | melanoma | CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O | Launched | true | ACH-000954 |
BRD-K13049116-001-04-0 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.998924 | -0.157823 | -0.000208 | 0.999506 | 0.026545 | null | BMS-754807 | IGF-1 inhibitor | AKT1, IGF1R | null | null | C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1 | Phase 2 | true | ACH-000954 |
BRD-K13390322-001-06-3 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.288268 | 4.89737 | 0.544646 | 0.78573 | 0.538459 | 0.641732 | AT-7519 | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK9 | null | null | Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1 | Phase 2 | true | ACH-000954 |
BRD-K13514097-001-04-6 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 1.028506 | -0.061537 | -0.023748 | 1 | 81,130.582658 | null | everolimus | mTOR inhibitor | MTOR | oncology, neurology/psychiatry, genetics, urology | breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO | Launched | true | ACH-000954 |
BRD-K13662825-001-07-5 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.394083 | 0.495484 | 0.163116 | 0.656899 | 0.009025 | 0.206894 | dinaciclib | CDK inhibitor | CDK1, CDK2, CDK5, CDK9 | null | null | CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO | Phase 3 | true | ACH-000954 |
BRD-K14109347-001-03-4 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.861027 | -0.225917 | -0.040091 | 0.933484 | 0.051533 | null | LY2603618 | CHK inhibitor | CHEK1 | null | null | Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1 | Phase 2 | true | ACH-000954 |
BRD-K15179879-001-03-2 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.122744 | 2.243679 | 0.722744 | 0.534693 | 0.058141 | 0.065918 | carfilzomib | proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9 | hematologic malignancy | multiple myeloma | CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1 | Launched | true | ACH-000954 |
BRD-K15600710-066-05-8 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.117577 | 4.088988 | 0.268074 | 0.925737 | 4.376874 | 4.673456 | obatoclax | BCL inhibitor | BCL2 | null | null | COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1, COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 | Phase 3 | true | ACH-000954 |
BRD-K16730910-001-10-7 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.34544 | 3.806634 | 0.330524 | 0.883375 | 1.775081 | 2.416395 | regorafenib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK | oncology | colorectal cancer, gastrointestinal stromal tumors (GIST) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1 | Launched | true | ACH-000954 |
BRD-K17555800-003-02-3 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.8666 | 2.63463 | -0.191407 | 0.89694 | 0.005539 | null | talmapimod | p38 MAPK inhibitor | MAPK11, MAPK14 | null | null | C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C | Phase 2 | true | ACH-000954 |
BRD-K17610631-001-03-3 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.601829 | 7.437574 | 0.19086 | 0.858996 | 0.311609 | null | indisulam | CDK inhibitor | CA1, CA12, CA14, CA2, CA6, CA7, CA9 | null | null | NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12 | Phase 2 | true | ACH-000954 |
BRD-K17743125-001-08-4 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.146529 | 6.35955 | 0.689373 | 0.852194 | 1.862498 | 1.966886 | belinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1 | Launched | true | ACH-000954 |
BRD-K19540840-001-09-4 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.817222 | 0.82862 | 0.007276 | 0.919002 | 0.13847 | null | saracatinib | src inhibitor | ABL1, LCK, SRC, YES1 | null | null | CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1 | Phase 2/Phase 3 | true | ACH-000954 |
BRD-K19687926-001-04-1 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 1.525429 | -0.047419 | -0.083695 | 1 | 1.960616 | null | lapatinib | EGFR inhibitor | EGFR, ERBB2 | oncology | breast cancer | CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1 | Launched | true | ACH-000954 |
BRD-K19796430-001-05-6 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 1.278951 | -0.013874 | -0.057855 | 1 | 0.455539 | null | sonidegib | smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1 | Launched | true | ACH-000954 |
BRD-K22064724-001-01-8 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 1.105505 | 4.670191 | -0.026887 | 1 | 0.00249 | null | napabucasin | STAT inhibitor | STAT3 | null | null | CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O | Phase 3 | true | ACH-000954 |
BRD-K22822991-001-02-3 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 1.30168 | -0.159393 | -0.003124 | 1 | 0.002771 | null | odanacatib | cathepsin inhibitor | CTSK | null | null | CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N | Phase 3 | true | ACH-000954 |
BRD-K23228615-001-02-8 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.774273 | 2.950407 | 0.11761 | 0.84781 | 0.0144 | null | GDC-0980 | mTOR inhibitor, PI3K inhibitor | FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK | null | null | C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1 | Phase 2 | true | ACH-000954 |
BRD-K23984367-001-07-5 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 1.198302 | -1.871901 | 0.02293 | 1 | 0.071627 | null | sorafenib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET | oncology | renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1 | Launched | true | ACH-000954 |
BRD-K26026438-001-01-0 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 1.586745 | -3.735885 | 0.258986 | 1 | 0.001357 | null | tucatinib | EGFR inhibitor | ERBB2 | null | null | Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 | Phase 2 | true | ACH-000954 |
BRD-K26657438-001-15-2 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.782595 | 0.026983 | -0.0458 | 0.899381 | 19.699606 | null | imiquimod | interferon inducer, toll-like receptor agonist | TLR7, TLR8 | dermatology, infectious disease, oncology | actinic keratosis (AK), genital warts, basal cell carcinoma (BCC) | CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12 | Launched | true | ACH-000954 |
BRD-K28822270-001-03-7 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.420458 | 0.299809 | 0.027283 | 0.716052 | 0.095657 | null | resminostat | HDAC inhibitor | HDAC1, HDAC3, HDAC6, HDAC8 | null | null | CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO | Phase 2 | true | ACH-000954 |
BRD-K29905972-001-06-3 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.743849 | 4.092898 | 0.10413 | 0.93865 | 0.978511 | null | axitinib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, FLT1, FLT4, KDR, PLK4 | oncology | renal cell carcinoma (RCC) | CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1 | Launched | true | ACH-000954 |
BRD-K30577245-001-05-0 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 1.018492 | -0.133371 | -0.07355 | 1 | 0.019284 | null | docetaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1 | oncology | breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC) | CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C | Launched | true | ACH-000954 |
BRD-K31698212-001-02-9 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 1.129231 | -0.04057 | -0.004396 | 1 | 76.482717 | null | icotinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1 | Launched | true | ACH-000954 |
BRD-K33379087-001-07-5 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 1.006937 | -0.170006 | -0.021608 | 1 | 0.840896 | null | tivantinib | tyrosine kinase inhibitor | MET | null | null | O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23 | Phase 3 | true | ACH-000954 |
BRD-K33610132-001-02-9 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 1.274599 | 0.09623 | -0.001994 | 1 | 0.399772 | null | rociletinib | EGFR inhibitor | EGFR | null | null | COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O | Phase 3 | true | ACH-000954 |
BRD-K33622447-066-01-9 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.640352 | 2.783406 | -0.027647 | 0.830744 | 0.103875 | null | abemaciclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1 | Launched | true | ACH-000954 |
BRD-K35520305-001-16-9 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 1.188388 | -0.020669 | -0.020638 | 1 | 771,230.890957 | null | dacarbazine | DNA alkylating agent | PGD, POLA2 | oncology, hematologic malignancy | melanoma, Hodgkin's lymphoma | CN(C)\N=N\c1[nH]cnc1C(N)=O, CN(C)\N=N\c1[nH]cnc1C(N)=O | Launched | true | ACH-000954 |
BRD-K36627727-001-05-4 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 1.342904 | -3.355397 | 0.265051 | 1 | 0.041951 | null | tamibarotene | retinoid receptor agonist | RARA, RARB | hematologic malignancy | acute promyelocytic leukemia (APL) | CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12 | Launched | true | ACH-000954 |
BRD-K37379014-001-02-0 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.643661 | 0.199296 | -0.285579 | 0.754053 | 0.000016 | null | filanesib | kinesin inhibitor, kinesin-like spindle protein inhibitor | KIF11 | null | null | CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F | Phase 3 | true | ACH-000954 |
BRD-K38332599-001-01-3 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.802065 | 1.507393 | 0.06995 | 0.943771 | 0.641585 | null | uprosertib | AKT inhibitor | AKT1, AKT2, AKT3 | null | null | Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1 | Phase 2 | true | ACH-000954 |
BRD-K38527262-300-01-0 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.50425 | 0.692301 | 0.131287 | 0.823811 | 0.329892 | null | atiprimod | JAK inhibitor, STAT inhibitor | JAK2, STAT3 | null | null | CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1 | Phase 2 | true | ACH-000954 |
BRD-K38852836-001-02-1 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.623823 | 1.335587 | 0.303561 | 0.796363 | 0.01308 | null | ganetespib | HSP inhibitor | HSP90AA1 | null | null | CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O | Phase 3 | true | ACH-000954 |
BRD-K41859756-001-06-8 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.727806 | 2.178204 | -0.029839 | 0.883858 | 0.039831 | null | NVP-AUY922 | HSP inhibitor | HSP90AA1, HSP90AB1 | null | null | CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O | Phase 2 | true | ACH-000954 |
BRD-K42495768-001-01-7 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.699828 | 1.153707 | 0.090899 | 0.964366 | 4.124711 | null | tasisulam | apoptosis stimulant | null | null | null | Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1 | Phase 3 | true | ACH-000954 |
BRD-K42805893-001-04-9 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 0.764551 | 0.452531 | 0.120522 | 0.893398 | 0.138717 | null | osimertinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12 | Launched | true | ACH-000954 |
BRD-K42828737-001-03-3 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 1.435979 | -2.980033 | -0.110492 | 1 | 0.221993 | null | sunitinib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET | oncology | gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET) | CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C | Launched | true | ACH-000954 |
BRD-K42898655-001-01-8 | ACH-000954 | HEC1A_ENDOMETRIUM | MTS010 | 1 | 2.046708 | 0.111676 | -0.024964 | 1 | 1,130.783636 | null | temsirolimus | mTOR inhibitor | MTOR | oncology | renal cell carcinoma (RCC) | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO | Launched | true | ACH-000954 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.